Relating to: health care costs omnibus, granting rule-making authority, making an appropriation, and providing a penalty. (FE)

AB 62 establishes a Prescription Drug Affordability Review Board to address prescription drug costs. The board, with members representing pharmaceutical companies, health insurers, healthcare providers, and the public, must meet quarterly and avoid conflicts of interest. Key provisions include creating a $500,000 annual grant program for healthcare providers to develop tools showing patients the cost of prescriptions (Section 601.415), launching a diabetes medication pilot project (Section 601.41), and repealing a section requiring copayments for certain Medicaid services (Section 7). This bill directly affects insurers, pharmacies, drug manufacturers, and healthcare providers who must disclose drug costs to patients.